Skip to main content

Table 3 Clinical and laboratory differences between baseline and the end of ketogenic phase

From: VLCKD: a real time safety study in obesity

Parameters Baseline End of phase 1 p value
Weight (kg) 94.38 ± 17.34 87.29 ± 15.99  < 0.001
BMI (kg/m2) 34.98 ± 5.43 32.35 ± 5.02  < 0.001
WC (cm) 106.16 ± 14.20) 99.24 ± 13.57  < 0.001
HC (cm) 120.53 ± 10.81 115.91 ± 9.70  < 0.001
WHR 0.88 ± 0.08 0.86 ± 0.09  < 0.001
Blood Glucose (mg/dL) 88.04 ± 8.95 82.60 ± 10.08 0.072
Insulin (mg/dL) 17.35 ± 13.83 8.05 ± 5.48 0.286
HOMA—IR 3.80 ± 2.79 1.74 ± 1.29 0.332
Tot Chol (mg/dL) 170.20 ± 40.77 144.72 ± 30.61  < 0.001
LDL Chol (mg/dL) 101.95 ± 29.11 81.40 ± 29.91 0.142
HDL Chol (mg/dL) 52.24 ± 12.17 49.86 ± 13.11 0.018
TG (mg/dL) 88.95 ± 30.77 86.14 ± 20.57 0.235
GFR (mL/min) 94.13 ± 19.00 89.00 ± 20.83 0.123
Creatinine (mg/dL) 0.77 ± 0.11 0.82 ± 0.16  < 0.001
Azotemia (mg/dL) 30.44 ± 8.94 34.89 ± 10.60 0.001
Uricemia (mg/dL) 5.29 ± 1.45 6.23 ± 1.69 0.054
AST (U/L) 20.50 ± 6.60 20.92 ± 6.32 0.022
ALT (U/L) 23.43 ± 9.85 22.90 ± 12.15 0.001
GGT (U/L) 17.82 ± 6.48 14.72 ± 5.25 0.003
Calcemia (mg/dL) 9.70 ± 0.75 9.90 ± 0.61 0.056
Sodiemia (mmol/L) 140.34 ± 2.72 140.53 ± 2.22 0.001
Potassiaemia (mmol/L) 4.41 ± 0.30 4.43 ± 0.33 0.452
  1. Data are expressed as n or mean ± SD
  2. BMI body mass index, WC waist circumference, HC hip circumference, WHR waist-to-hip-ratio, HOMA-IR homeostasis model of assessment-IR, Tot Chol total cholesterol, LDL-chol low-dense-lipoprotein cholesterol, HDL-chol high dense lipoprotein cholesterol, TG triglycerides, GFR glomerular filtration rate, AST aspartate aminotransferase, ALT alanine transaminase, GGT gamma-glutamyl transferase